PMID: 8099741Jan 1, 1993

Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs

Pharmacology & Therapeutics
Bart A Ellenbroek

Abstract

Forty years after the first clinical report on the effectiveness of chlorpromazine in psychiatric patients, neuroleptic drugs are still the most widely used drugs in the treatment of schizophrenia. Indeed, there are no other drugs which have proven to be as effective in the treatment of this severe psychiatric disorder. Yet, there are still many unresolved problems relating to neuroleptic drugs. The present review gives a comprehensive overview of our knowledge (and our lack of knowledge) with respect to the clinical and preclinical effects of neuroleptic drugs and tries to integrate this knowledge in order to identify the neuronal mechanisms underlying the therapeutic and side effects of neuroleptic drugs.

References

Jan 1, 1995·Journal of Neural Transmission. General Section·I M WhiteG V Rebec
Nov 19, 2013·Clinical Drug Investigation·Alfonso Rodríguez-Martínez, Carlos Guzmán Quilo
Jan 1, 1995·Neuroscience and Biobehavioral Reviews·J F LiégeoisJ Damas
Jan 1, 1996·Neuroscience and Biobehavioral Reviews·M L Wadenberg
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mark A Geyer, Bart A Ellenbroek
Sep 6, 2000·Pharmacology, Biochemistry, and Behavior·G CrescimannoG Amato
Aug 2, 2002·Pharmacology, Biochemistry, and Behavior·Jun-ichi KarasawaKazutoshi Horikomi
Aug 1, 1997·Pharmacology, Biochemistry, and Behavior·B M Kelley, J H Porter
Jun 4, 1998·Pharmacology, Biochemistry, and Behavior·L Costa-CamposE Elisabetsky
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·S A JosselynR J Beninger
Feb 19, 1998·Schizophrenia Research·J L WaddingtonE O'Callaghan
Mar 19, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·E Obuchowicz, J Turchan
Jul 28, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·E Obuchowicz, J Turchan
Mar 21, 2002·Acta Physiologica Scandinavica·N C McNaughtonA D Randall
Mar 22, 2006·Evidence-based Complementary and Alternative Medicine : ECAM·E Elisabetsky, L Costa-Campos
Oct 1, 1996·Clinical and Experimental Pharmacology & Physiology·S M Pond
Jan 1, 1994·The European Journal of Neuroscience·Bart A EllenbroekA R Cools
Aug 23, 2006·Acta Pharmacologica Sinica·Bart A EllenbroekGuo-zhang Jin
Aug 16, 2006·Neuro-degenerative Diseases·Oscar P Dall'IgnaDiogo R Lara
Aug 4, 2004·Psychopharmacology·Adriano B L TortDiogo R Lara
Aug 19, 2014·The Journal of Pharmacy and Pharmacology·Anna PartykaAnna Wesołowska
Sep 26, 2015·Journal of Enzyme Inhibition and Medicinal Chemistry·Grażyna Chłoń-RzepaAnna Wesołowska
Mar 18, 2011·British Journal of Pharmacology·Jared W YoungMark A Geyer
Sep 1, 1995·Biological Psychiatry·B Kirkpatrick, W T Carpenter

Citations

May 28, 1976·Psychopharmacologia·D L GarverJ Haraszti
Aug 1, 1976·Canadian Journal of Physiology and Pharmacology·C Erzin-WatersP Seeman
Jul 16, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·H H KellerW Haefely
Jul 6, 1978·Psychopharmacology·G M SimpsonB Zoubok
Sep 1, 1978·The Journal of Pharmacy and Pharmacology·B CostallR J Naylor
Oct 1, 1978·The Journal of Pharmacy and Pharmacology·B CostallR T Owen
Dec 15, 1978·Psychopharmacology·P Muller, P Seeman
Mar 28, 1979·Psychopharmacology·T A Stern, W H Anderson
Dec 1, 1979·Psychosomatics·R A Bernstein
Mar 5, 1977·Lancet·H J SennW Pöldinger
Jul 1, 1977·Brain Research·S Y Assaf, J J Miller
Aug 8, 1979·Psychopharmacology·L BjerkenstedtG Sedval
Aug 1, 1975·European Journal of Pharmacology·B H Westerink, J Korf
Jan 1, 1975·Comprehensive Psychiatry·T Van Putten
Aug 1, 1977·The British Journal of Psychiatry : the Journal of Mental Science·R H Belmaker, D Wald
Jun 11, 1979·Life Sciences·C J Niemegeers, P F Janssen
Jan 1, 1979·International Anesthesiology Clinics·M A Denborough
Aug 31, 1977·Psychopharmacology·D E Casey, D Denney
Jan 31, 1978·Psychopharmacology·G M SimpsonR K Shrivastava
May 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·G P Sheppard
Dec 1, 1979·Pharmacology, Biochemistry, and Behavior·G R Wenger
Feb 7, 1977·European Journal of Pharmacology·C Ezrin-Waters, P Seeman
Jan 1, 1977·Folia Psychiatrica Et Neurologica Japonica·H ItohY Koga
Jan 1, 1978·Schizophrenia Bulletin·G Claridge
May 1, 1976·Journal of Clinical Pharmacology·G Chouinard, L Annable
Dec 21, 1976·Psychopharmacology·P Danneskiold-Samsøoe, V Pedersen
Mar 11, 1977·European Journal of Clinical Pharmacology·B Anderman, R W Griffith
Mar 11, 1977·European Journal of Clinical Pharmacology·J Idänpään-HeikkiläI P Palva
Jan 1, 1977·American Journal of Hematology·R T CanosoD Deykin

Related Concepts

Antipsychotic Effect
Neuroleptic Malignant Syndrome
Schizophrenia
Fetishism (Psychiatric)
Synaptic Receptors
Dopamine Receptor

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.